Revenue GuidanceManagement provided 2025 revenue guidance of approximately $21.5M, an expected decrease from 2024, as the company intends to focus its efforts primarily on obtaining regulatory approval.
Risk FactorsRisks include clinical, competition, regulatory, commercial, legal and intellectual property, manufacturing, and dilution.